DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...

Clinical worsening also occurred less frequently with treprostinil ...

Baseimmune unveils a new multi-pathway immunotherapy strategy, applying its computational protein design platform to develop next-generation therapies for fibrosis. Fibrosis is driven by complex and ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...

CLEVELAND — The number of people diagnosed with idiopathic pulmonary fibrosis is expected to grow substantially over the next decade, according to new forecasts from a global health data analytics ...

United Therapeutics (NasdaqGS:UTHR) reported full Phase 3 TETON-2 trial data for nebulized Tyvaso in idiopathic pulmonary fibrosis, published in the New England Journal of Medicine. The study showed ...

A biomarker panel for IPF may identify RA patients at higher risk for ILD, supporting biological overlap between IPF and RA-ILD. The study involved over 2500 US veterans and showed strong associations ...

The effect of pollution exposure on IPF severity and progression was not modified by MUC5B promotor polymorphism or telomere length. Long-term exposure to fine particulate matter is associated with a ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

The Pulmonary Fibrosis Foundation's Care Center Network has grown to include 96 sites in 40 states as part of its first expansion since 2023, marking a milestone in strengthening access to ...